Ceftobiprole medocaril

Drug Profile

Ceftobiprole medocaril

Alternative Names: BAL-5788; BAL-9141; Ceftobiprole; JNJ 30982081; Mabelio; RO-63-9141; RO-639141-000; RO-65-5788; Zeftera; Zevtera

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Basilea Pharmaceutica; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development
  • Class Cephalosporins; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Nosocomial pneumonia
  • No development reported Paediatric infections; Skin and soft tissue infections

Most Recent Events

  • 21 Apr 2017 Basilia Pharmaceutica plans two phase III trials for Skin and soft tissue infections and Bacterimia
  • 02 Dec 2016 Phase-III clinical trials in Nosocomial pneumonia and Community-acquired pneumonia (In infants, In children, In adolescents, Treatment-resistant) in Hungary (IV) (EudraCT2013-004615-45)
  • 20 Sep 2016 Ceftobiprole medocaril licensed to Unimedic Pharma in Sweden, Denmark, Norway and Finland for import and commercialisation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top